Your browser doesn't support javascript.
loading
Phase I/II trial of weekly bortezomib with lenalidomide and dexamethasone in first relapse or primary refractory myeloma.
Broijl, Annemiek; Kersten, Marie-José; Alemayehu, Wendimagegn Ghidey; Levin, Mark-David; de Weerdt, Okke; Vellenga, Edo; Meijer, Ellen; Wittebol, Shulamit; Tanis, Bea C; Cornelisse, Petra B; Stevens-Kroef, Marian; Bos, Gerard M J; Wijermans, Pierre W; Lokhorst, Henk; Sonneveld, Pieter.
Afiliação
  • Broijl A; Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands a.broyl@erasmusmc.nl.
  • Kersten MJ; Department of Hematology, Academic Medical Center (AMC), Amsterdam, the Netherlands.
  • Alemayehu WG; HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
  • Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, the Netherlands.
  • de Weerdt O; Department of Hematology, Antonius Hospital, Nieuwegein, the Netherlands.
  • Vellenga E; Department of Hematology, University Medical Center (UMCG), Groninge, the Netherlands.
  • Meijer E; Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands.
  • Wittebol S; Department of Hematology, Meander Medical Center, Amersfoort, the Netherlands.
  • Tanis BC; Department of Internal Medicine, Groene Hart Ziekenhuis, Gouda, the Netherlands.
  • Cornelisse PB; HOVON Data Center, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
  • Stevens-Kroef M; Working group on Hemato-Oncologic Genome Diagnostics (WHGD), Department of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Bos GM; Department of Hematology, University Hospital, Maastricht, the Netherlands.
  • Wijermans PW; Department of Hematology, HAGA Hospital, the Hague, the Netherlands.
  • Lokhorst H; Department of Hematology, VU medical center, Amsterdam (VUmc), the Netherlands.
  • Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute (EMC), Rotterdam, the Netherlands.
Haematologica ; 101(4): e149-52, 2016 Apr.
Article em En | MEDLINE | ID: mdl-26659914
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Segunda Neoplasia Primária / Bortezomib / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Talidomida / Dexametasona / Protocolos de Quimioterapia Combinada Antineoplásica / Segunda Neoplasia Primária / Bortezomib / Mieloma Múltiplo Tipo de estudo: Clinical_trials / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Haematologica Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Holanda País de publicação: Itália